Back to results
US 2022/0106603 A1Published application
Engineered dysbiosis-sensing probiotic for clostridium difficile infections and recurring infections management
AssigneeNational University of Singapore
InventorsElvin KOH, In Young HWANG, Matthew Wook CHANG
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of metabolic engineering bacteria cells to produce bile salt hydrolase to inhibit the germination of C. difficile endospores and colonisation within the human gastrointestinal tract. The bile salt hydrolase is operably linked to a sialic acid-inducible promoter, pNanA, of which pNanA is in turn controlled by the repressor nanR. The recombinant bacteria expressing the bile salt hydrolase can be a probiotic strain to be used for prophylaxis or treatment of C. difficile infection.
Claims23
1-27. (canceled)
An expression cassette comprising;
- i. a bile salt hydrolase gene, and
- ii. a sialic acid-responsive promoter operably linked to the bile salt hydrolase gene.
Dependencies are inferred from the claim text.